In a recent clinical study, studying more than 1000 PCa patients under Enz treatment has shown that the expression of the oncoprotein CREB5 was abnormally high in ADT resistant tumors, which is due to an increased copy number of CREB5. Here, CREB5 is linked to posterior cortical atrophy.